TITLE

Influence of Helicobacter pylori Eradication Therapy on 13C Aminopyrine Breath Test: Comparison Among Omeprazole-, Lansoprazole-, or Pantoprazole-Containing Regimens

AUTHOR(S)
Giannini, Edoardo; Romagnoli, Paola; Fasoli, Alberto; Chiarbonello, Bruno; Malfatti, Federica; Botta, Federica; Risso, Domenico; Lantieri, Pasquale B.; Savarino, Vincenzo; Testa, Roberto
PUB. DATE
October 2000
SOURCE
American Journal of Gastroenterology;Oct2000, Vol. 95 Issue 10, p2762
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: Proton pump inhibitors and antimicrobial agents are widely used to eradicate Helicobacter pylori (H. pylori) infection. In the general population the prevalence of infection and of polypharmacy increases the possibility of drug-drug interactions during H. pylori eradication therapy. The purpose of the present study was to assess the prevalence, degree, and clinical relevance of metabolic interference with the cytochrome P450 enzymatic system occurring during 1 wk of administration of omeprazole, lansoprazole, or pantoprazole followed by the association of clarithromycin and metronidazole for another week. The 13C aminopyrine breath test (ABT) was chosen to screen for possible interactions. METHODS: We studied 30 patients referred to our Unit for H. pylori eradication therapy. They were randomized to receive either omeprazole (20 mg b.i.d.), lansoprazole (30 mg b.i.d.), or pantoprazole (40 mg b.i.d.) for 2 wk. During the second week clarithromycin (250 mg b.i.d.) and metronidazole (500 mg b.i.d.) were added. ABT was performed before, and at the end of the first and second week of therapy. Percentage of the administered dose of 13C recovered per hour at the peak (percent 13C dose/h at the peak) and cumulative percentage of administered dose of 13C recovered over time at 120 min (percent 13C dose cum20) were the ABT evaluated parameters. RESULTS: At baseline all patients showed a normal liver function. In individual patients during treatment we observed various liver metabolic interactions both as inhibition and induction, as well as after the first and the second week of therapy. However, mean modifications of the ABT parameters during the 2 weeks of therapy were not statistically significant compared to baseline values. None of the patients who had ABT variations complained of side effects. CONCLUSIONS: H. pylori eradication therapy interferes with cytochrome P450-dependent liver metabolic activity. However, the clinical relevance of these metabolic interactions is not yet apparent, and further investigation is needed. H. pylori eradication therapy appears safe, but these interactions should be considered in the choice of proton pump inhibitor and antimicrobial agents.
ACCESSION #
17623954

 

Related Articles

  • Rabeprazole. Prakash, A.; Faulds, D. // Drugs;Feb1998, Vol. 55 Issue 2, p261 

    â–´ Rabeprazole is a proton pump inhibitor with antisecretory properties. In vitro animal experiments have indicated that the inhibition of the proton pump by rabeprazole is partially reversible. â–´ Rabeprazole has 2- to 10-fold greater antisecretory activity than omeprazole in vitro....

  • Helicobacter pylori Treatment: A Practical Approach. Vakil, Nimish // American Journal of Gastroenterology;Mar2006, Vol. 101 Issue 3, p497 

    The treatment of Helicobacter pylori infection has become complicated by the lack of new treatment regimens and the emergence of drug resistant strains of H. pylori. Metronidazole and clarithromycin resistance are common in developed countries. Eradication rates have been falling in trials and...

  • Efficacy of metronidazole for the treatment of clarithromycin-resistantHelicobacter pyloriinfection in a Japanese population. Shimoyama, Tadashi; Fukuda, Shinsaku; Mikami, Tatsuya; Fukushi, Michio; Munakata, Akihiro // Journal of Gastroenterology;2004, Vol. 39 Issue 10, p927 

    Background. Eradication of Helicobacter pylori has become a common treatment for several diseases. There is an increase in antibiotic-resistant strains, which causes the failure of eradication. The aim of this study was to investigate the usefulness of metronidazole for the treatment of H....

  • Predicting Drug Interaction Potential With a Physiologically Based Pharmacokinetic Model: A Case Study of Telithromycin, a Time-Dependent CYP3A Inhibitor. Vieira, Md L T; Zhao, P; Berglund, E G; Reynolds, K S; Zhang, L; Lesko, L J; Huang, S-M // Clinical Pharmacology & Therapeutics;Apr2012, Vol. 91 Issue 4, p700 

    Telithromycin is a substrate and an inhibitor of cytochrome P450 3A (CYP3A4), with dose- and time-dependent nonlinear pharmacokinetics (PK). We hypothesized that the time-dependent inhibition (TDI) of CYP3A4 was responsible for the nonlinear PK of telithromycin and then used physiologically...

  • Interaction between Levothyroxine and Indinavir in a Patient with HIV Infection. Lanzafame, M.; Trevenzoli, M.; Faggian, F.; Marcati, P.; Gatti, F.; Carolo, G.; Concia, E. // Infection;Feb2002, Vol. 30 Issue 1, p54 

    Drug interactions are an important and emerging problem in the treatment of HIV-infected patients. Protease inhibitors, like nonnucleoside reverse transcriptase inhibitors, are metabolized by the cytochrome P-450 enzyme system and each of these antiretroviral. agents may interact with other...

  • What regime eradicate Helicobacter pylori? Hansen, Laura B. // Journal of Family Practice;Oct2003, Vol. 52 Issue 10, p799 

    The article examines some effective therapies for Helicobacter pylori eradication. A superior therapy in eradicating Helicobacter pylori is a fourteen-day triple therapy with a proton pump inhibitor (PPI) along with clarithromycin and a choice between amoxicillin or metronidazole. A seven-day...

  • New molecular mechanisms of resistance of Helicobacter pylori to clarithromycin. Pietroiusti, A.; Fontana, C.; Minelli, S.; Favalli, C.; Magrini, A.; Favaro, M.; Bergamaschi, A.; Iannaccone, U.; Galante, A. // Gut;Sep2002 Supplement 2, Vol. 51, pA3 

    Currently used therapies for Helicobacter pylori eradication include two antimicrobial (clarithromycin plus amoxicillin or metronidazole) plus a proton pump inhibitor. Although H. pylori is susceptible to most antimicrobial agents in vitro, in vivo eradication may difficult (12). The increased...

  • Neutralization of Helicobacter pylori cytotoxicity on vero cells by omeprazole micronized. Navid, S. Latifi; Siavoshi, F.; Mokhtari-Azad, T.; Malekzadeh, R.; Sohrabi, M.; Massarrat, S. // Gut;Sep2002 Supplement 2, Vol. 51, pA16 

    Backgrounds/Aims: Omeprazole is a gastric parietal cells proton pump inhibitor that is also active against H. pylori in vitro. This study was designed to examine the neutralization of H. pylori cytotoxicity on Vero cells by omeprazole micronized in strains isolated from gastritis, ulcer, cancer...

  • Molecular mechanisms of Helicobacter pylori resistance to metronidazole. Pietroiusti, A.; Fontana, C.; Favaro, M.; Minelli, S.; Favalli, C.; Magrini, A.; Bergamaschi, A.; Iannaccone, U.; Galante, A. // Gut;Sep2002 Supplement 2, Vol. 51, pA4 

    Triple-drug regimens (metronidazole in combination with either amoxicillin or clarithromicin and a proton pump inhibitor) are highly effective in treating Helicobacter pylori infection, but bacterial resistance to metronidazole and clarithromycin, is a serious and increasing problem. It has been...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics